These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 8726925

  • 1. Importance of baseline cotinine plasma values in smoking cessation: results from a double-blind study with nicotine patch.
    Paoletti P, Fornai E, Maggiorelli F, Puntoni R, Viegi G, Carrozzi L, Corlando A, Gustavsson G, Säwe U, Giuntini C.
    Eur Respir J; 1996 Apr; 9(4):643-51. PubMed ID: 8726925
    [Abstract] [Full Text] [Related]

  • 2. High-dose nicotine patch therapy. Percentage of replacement and smoking cessation.
    Dale LC, Hurt RD, Offord KP, Lawson GM, Croghan IT, Schroeder DR.
    JAMA; 1995 Nov 01; 274(17):1353-8. PubMed ID: 7563559
    [Abstract] [Full Text] [Related]

  • 3. Application of serum nicotine and plasma cotinine concentrations to assessment of nicotine replacement in light, moderate, and heavy smokers undergoing transdermal therapy.
    Lawson GM, Hurt RD, Dale LC, Offord KP, Croghan IT, Schroeder DR, Jiang NS.
    J Clin Pharmacol; 1998 Jun 01; 38(6):502-9. PubMed ID: 9650539
    [Abstract] [Full Text] [Related]

  • 4. Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up. One-year outcome and percentage of nicotine replacement.
    Hurt RD, Dale LC, Fredrickson PA, Caldwell CC, Lee GA, Offord KP, Lauger GG, Marŭsić Z, Neese LW, Lundberg TG.
    JAMA; 1994 Feb 23; 271(8):595-600. PubMed ID: 8301791
    [Abstract] [Full Text] [Related]

  • 5. Weight change after smoking cessation using variable doses of transdermal nicotine replacement.
    Dale LC, Schroeder DR, Wolter TD, Croghan IT, Hurt RD, Offord KP.
    J Gen Intern Med; 1998 Jan 23; 13(1):9-15. PubMed ID: 9462489
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study.
    Schnoll RA, Patterson F, Wileyto EP, Tyndale RF, Benowitz N, Lerman C.
    Pharmacol Biochem Behav; 2009 Mar 23; 92(1):6-11. PubMed ID: 19000709
    [Abstract] [Full Text] [Related]

  • 10. Predicting smoking cessation. Who will quit with and without the nicotine patch.
    Kenford SL, Fiore MC, Jorenby DE, Smith SS, Wetter D, Baker TB.
    JAMA; 1994 Feb 23; 271(8):589-94. PubMed ID: 8301790
    [Abstract] [Full Text] [Related]

  • 11. Varying nicotine patch dose and type of smoking cessation counseling.
    Jorenby DE, Smith SS, Fiore MC, Hurt RD, Offord KP, Croghan IT, Hays JT, Lewis SF, Baker TB.
    JAMA; 1995 Nov 01; 274(17):1347-52. PubMed ID: 7563558
    [Abstract] [Full Text] [Related]

  • 12. Escalating doses of transdermal nicotine in heavy smokers: effects on smoking behavior and craving.
    Selby P, Andriash K, Zawertailo L, Persad D, Zack M, Busto UE.
    J Clin Psychopharmacol; 2013 Oct 01; 33(5):667-74. PubMed ID: 23963055
    [Abstract] [Full Text] [Related]

  • 13. High dose transdermal nicotine therapy for heavy smokers: safety, tolerability and measurement of nicotine and cotinine levels.
    Fredrickson PA, Hurt RD, Lee GM, Wingender L, Croghan IT, Lauger G, Gomez-Dahl L, Offord KP.
    Psychopharmacology (Berl); 1995 Dec 01; 122(3):215-22. PubMed ID: 8748390
    [Abstract] [Full Text] [Related]

  • 14. Symptoms of nicotine toxicity in subjects achieving high cotinine levels during nicotine replacement therapy.
    Tonstad S, Gustavsson G, Kruse E, Walmsley JM, Westin Å.
    Nicotine Tob Res; 2014 Sep 01; 16(9):1266-71. PubMed ID: 24852574
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia.
    Evins AE, Cather C, Culhane MA, Birnbaum A, Horowitz J, Hsieh E, Freudenreich O, Henderson DC, Schoenfeld DA, Rigotti NA, Goff DC.
    J Clin Psychopharmacol; 2007 Aug 01; 27(4):380-6. PubMed ID: 17632223
    [Abstract] [Full Text] [Related]

  • 18. Smokers deprived of cigarettes for 72 h: effect of nicotine patches on craving and withdrawal.
    Teneggi V, Tiffany ST, Squassante L, Milleri S, Ziviani L, Bye A.
    Psychopharmacology (Berl); 2002 Nov 01; 164(2):177-87. PubMed ID: 12404080
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Effects of transdermal nicotine as an adjunct in smoking cessation therapy. A double-blind randomized study controlled with placebo].
    Daughton DM, Heatley SA, Prendergast JJ, Causey D, Knowles M, Rolf CN, Cheney RA, Hatlelid K, Thompson AB, De Blasio F.
    Arch Monaldi Mal Torace; 1992 Nov 01; 47(1-6):17-29. PubMed ID: 1306633
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.